We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer's Aliqopa Gets Breakthrough Therapy Status by FDA
Read MoreHide Full Article
Bayer Aktiengesellschaft (BAYRY - Free Report) announced that the FDA granted Breakthrough Therapy designation to Aliqopa (copanlisib) for the treatment of adult patients with relapsed marginal zone lymphoma (MZL), who have received at least two prior therapies. MZL is an indolent form of non-Hodgkin’s lymphoma (iNHL) and accounts for about 10% of all non-Hodgkin’s lymphoma in the United States.
The Breakthrough Therapy designation is aimed at accelerating the development and review of drugs intended to treat serious or life-threatening diseases.
Aliqopa is a pan-PI3K inhibitor, with predominant activity against the PI3K-alpha and PI3K-delta isoforms expressed in malignant B-cells, developed by Bayer.
The Breakthrough Therapy designation was based on data from the MZL subgroup of the pivotal phase II CHRONOS-1 study that led to accelerated approval of Aliqopa in the United States for the treatment of adult patients with relapsed follicular lymphoma (FL), who have received at least two prior systemic therapies. The data from the CHRONOS-1 study showed efficacy of the drug in patients with iNHL, who have received at least two prior therapies, including those with relapsed or refractory MZL.
Shares of Bayer have declined 10.8% year to date against the industry’s growth of 0.9%.
Bayer is conducting two additional phase III studies — CHRONOS-3 and CHRONOS-4 — to evaluate the efficacy and safety of Aliqopa in combination with other therapies in iNHL (including MZL) patients, who have relapsed following one or more prior therapies.
We remind investors that recently, the FDA approved Celgene Corporation’s Revlimid (lenalidomide) in combination with a rituximab product (R²) for the treatment of adult patients with previously treated FL or MZL. This is the first combination regimen for patients with these indolent forms of non-Hodgkin lymphoma (NHL) that does not include chemotherapy.
Bristol-Myers’ earnings per share estimates have moved up from $4.78 to $5.03 for 2020 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters, with average beat of 11.85%.
Merck’s earnings per share estimates have moved up from $4.65 to $4.72 for 2019 and from $5.17 to $5.20 for 2020 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters, with average beat of 5.67%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Bayer's Aliqopa Gets Breakthrough Therapy Status by FDA
Bayer Aktiengesellschaft (BAYRY - Free Report) announced that the FDA granted Breakthrough Therapy designation to Aliqopa (copanlisib) for the treatment of adult patients with relapsed marginal zone lymphoma (MZL), who have received at least two prior therapies. MZL is an indolent form of non-Hodgkin’s lymphoma (iNHL) and accounts for about 10% of all non-Hodgkin’s lymphoma in the United States.
The Breakthrough Therapy designation is aimed at accelerating the development and review of drugs intended to treat serious or life-threatening diseases.
Aliqopa is a pan-PI3K inhibitor, with predominant activity against the PI3K-alpha and PI3K-delta isoforms expressed in malignant B-cells, developed by Bayer.
The Breakthrough Therapy designation was based on data from the MZL subgroup of the pivotal phase II CHRONOS-1 study that led to accelerated approval of Aliqopa in the United States for the treatment of adult patients with relapsed follicular lymphoma (FL), who have received at least two prior systemic therapies. The data from the CHRONOS-1 study showed efficacy of the drug in patients with iNHL, who have received at least two prior therapies, including those with relapsed or refractory MZL.
Shares of Bayer have declined 10.8% year to date against the industry’s growth of 0.9%.
Bayer is conducting two additional phase III studies — CHRONOS-3 and CHRONOS-4 — to evaluate the efficacy and safety of Aliqopa in combination with other therapies in iNHL (including MZL) patients, who have relapsed following one or more prior therapies.
We remind investors that recently, the FDA approved Celgene Corporation’s Revlimid (lenalidomide) in combination with a rituximab product (R²) for the treatment of adult patients with previously treated FL or MZL. This is the first combination regimen for patients with these indolent forms of non-Hodgkin lymphoma (NHL) that does not include chemotherapy.
Bayer Aktiengesellschaft Price
Bayer Aktiengesellschaft price | Bayer Aktiengesellschaft Quote
Zacks Rank & Stocks to Consider
Bayer currently carries a Zacks Rank #3 (Hold).
Some other better-ranked stocks in the health care sector include Bristol-Myers Squibb Company (BMY - Free Report) and Merck and Co., Inc. (MRK - Free Report) . While Bristol-Myers carries a Zacks Rank #1 (Strong Buy), Merck carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Bristol-Myers’ earnings per share estimates have moved up from $4.78 to $5.03 for 2020 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters, with average beat of 11.85%.
Merck’s earnings per share estimates have moved up from $4.65 to $4.72 for 2019 and from $5.17 to $5.20 for 2020 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters, with average beat of 5.67%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>